VACCINE EFFICACY ASSESSMENT
VACCINE EFFICACY ASSESSMENT
Evaluating the effectiveness of vaccines is a critical step in infectious disease research and public health response. Vaccine efficacy is typically assessed by measuring the levels of virus-specific antibodies produced in response to immunization.
Allianz Bio, in collaboration with ACRO Biosystems, offers ready-to-use antibody Titer ELISA kits covering SARS-CoV-2 variants (e.g., Delta, Omicron, XBB.1.5) and viral proteins (spike, RBD, nucleocapsid).
Kits support multiple species—human, mouse, monkey, cotton rat—and include targets like RSV, HSV-2, Rabies, and Varicella Zoster, ensuring sensitive, reliable results for vaccine research and immune monitoring.
Key Features
- Variant-Specific Coverage – Includes kits targeting SARS-CoV-2 variants (e.g., Delta, Omicron, XBB.1.5) and viral proteins like spike trimer, S1, RBD, and nucleocapsid.
- Multi-Species Compatibility – Validated for human, mouse, monkey, and cotton rat samples for both preclinical and clinical studies.
- Expanded Viral Targets – Supports research on RSV, HSV-2, Rabies, and Varicella Zoster for comprehensive vaccine evaluation.
- High Sensitivity and Reliability – Offers accurate, reproducible results to support immune monitoring and antibody quantification.
- Ready-to-Use Format – Streamlines workflow with validated, easy-to-use kits for rapid deployment in vaccine research.
More About Product
- Serologic ELISA assay kits targeting IgG antibodies against specific viral antigens—such as spike protein, RBD (receptor binding domain), or nucleocapsid protein—are commonly used for this purpose across various species (human, mouse, monkey, cotton rat).
- These assays help researchers determine immune protection levels, track immune responses to different virus variants, and guide vaccine improvement.
